FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387616251> ?p ?o ?g. }

• W4387616251 abstract "Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model." @default.
• W4387616251 created "2023-10-14" @default.
• W4387616251 creator A5001987856 @default.
• W4387616251 creator A5004768421 @default.
• W4387616251 creator A5016239256 @default.
• W4387616251 creator A5029418130 @default.
• W4387616251 creator A5029548910 @default.
• W4387616251 creator A5035644708 @default.
• W4387616251 creator A5040449497 @default.
• W4387616251 creator A5043979412 @default.
• W4387616251 creator A5050235154 @default.
• W4387616251 creator A5052122924 @default.
• W4387616251 creator A5070215692 @default.
• W4387616251 creator A5077243123 @default.
• W4387616251 creator A5085558462 @default.
• W4387616251 creator A5088518431 @default.
• W4387616251 creator A5089633502 @default.
• W4387616251 date "2023-10-13" @default.
• W4387616251 modified "2023-10-17" @default.
• W4387616251 title "Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study" @default.
• W4387616251 cites W2043904711 @default.
• W4387616251 cites W2132379894 @default.
• W4387616251 cites W2157096396 @default.
• W4387616251 cites W2289712604 @default.
• W4387616251 cites W2560688864 @default.
• W4387616251 cites W2582671354 @default.
• W4387616251 cites W2588916311 @default.
• W4387616251 cites W2604441970 @default.
• W4387616251 cites W2745624257 @default.
• W4387616251 cites W2765763462 @default.
• W4387616251 cites W2769143604 @default.
• W4387616251 cites W2777192533 @default.
• W4387616251 cites W2810609012 @default.
• W4387616251 cites W2885614544 @default.
• W4387616251 cites W2886065680 @default.
• W4387616251 cites W2890398072 @default.
• W4387616251 cites W2898518424 @default.
• W4387616251 cites W2904366723 @default.
• W4387616251 cites W2943108118 @default.
• W4387616251 cites W2994692693 @default.
• W4387616251 cites W3033612535 @default.
• W4387616251 cites W3036701611 @default.
• W4387616251 cites W3090670623 @default.
• W4387616251 cites W3115068211 @default.
• W4387616251 cites W3118924526 @default.
• W4387616251 cites W3123489934 @default.
• W4387616251 cites W3139470044 @default.
• W4387616251 cites W3213374286 @default.
• W4387616251 cites W3217429522 @default.
• W4387616251 cites W4220968001 @default.
• W4387616251 cites W4296513710 @default.
• W4387616251 doi "https://doi.org/10.1038/s41598-023-44103-9" @default.
• W4387616251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37833455" @default.
• W4387616251 hasPublicationYear "2023" @default.
• W4387616251 type Work @default.
• W4387616251 citedByCount "0" @default.
• W4387616251 crossrefType "journal-article" @default.
• W4387616251 hasAuthorship W4387616251A5001987856 @default.
• W4387616251 hasAuthorship W4387616251A5004768421 @default.
• W4387616251 hasAuthorship W4387616251A5016239256 @default.
• W4387616251 hasAuthorship W4387616251A5029418130 @default.
• W4387616251 hasAuthorship W4387616251A5029548910 @default.
• W4387616251 hasAuthorship W4387616251A5035644708 @default.
• W4387616251 hasAuthorship W4387616251A5040449497 @default.
• W4387616251 hasAuthorship W4387616251A5043979412 @default.
• W4387616251 hasAuthorship W4387616251A5050235154 @default.
• W4387616251 hasAuthorship W4387616251A5052122924 @default.
• W4387616251 hasAuthorship W4387616251A5070215692 @default.
• W4387616251 hasAuthorship W4387616251A5077243123 @default.
• W4387616251 hasAuthorship W4387616251A5085558462 @default.
• W4387616251 hasAuthorship W4387616251A5088518431 @default.
• W4387616251 hasAuthorship W4387616251A5089633502 @default.
• W4387616251 hasBestOaLocation W43876162511 @default.
• W4387616251 hasConcept C121608353 @default.
• W4387616251 hasConcept C126322002 @default.
• W4387616251 hasConcept C143998085 @default.
• W4387616251 hasConcept C167135981 @default.
• W4387616251 hasConcept C2775949291 @default.
• W4387616251 hasConcept C2777701055 @default.
• W4387616251 hasConcept C2780057760 @default.
• W4387616251 hasConcept C2780352672 @default.
• W4387616251 hasConcept C2908647359 @default.
• W4387616251 hasConcept C2911057145 @default.
• W4387616251 hasConcept C3019882237 @default.
• W4387616251 hasConcept C535046627 @default.
• W4387616251 hasConcept C71924100 @default.
• W4387616251 hasConcept C99454951 @default.
• W4387616251 hasConceptScore W4387616251C121608353 @default.
• W4387616251 hasConceptScore W4387616251C126322002 @default.
• W4387616251 hasConceptScore W4387616251C143998085 @default.
• W4387616251 hasConceptScore W4387616251C167135981 @default.
• W4387616251 hasConceptScore W4387616251C2775949291 @default.
• W4387616251 hasConceptScore W4387616251C2777701055 @default.
• W4387616251 hasConceptScore W4387616251C2780057760 @default.
• W4387616251 hasConceptScore W4387616251C2780352672 @default.
• W4387616251 hasConceptScore W4387616251C2908647359 @default.
• W4387616251 hasConceptScore W4387616251C2911057145 @default.
• W4387616251 hasConceptScore W4387616251C3019882237 @default.
• W4387616251 hasConceptScore W4387616251C535046627 @default.
• W4387616251 hasConceptScore W4387616251C71924100 @default.

• next